Whole Proteome Analysis of Multiple Myeloma Patient Samples Provides New Insights into IMiD/CELMoD Resistance (IMS 2026) - Sep 11, 2026 - Abstract #PA-528; Pres time: Sep 23, 2026; " We analysed proteomic changes associated with relapse on lenalidomide (Len) therapy using paired baseline and relapse CD138+ samples from patients enrolled in the Myeloma XI trial. In a separate analysis we explored degradation profiles in patient MM cells (CD138+ samples from IMiD sensitive and resistant patients) treated ex vivo with IMiDs/CELMoDs (Len 10uM, pomalidomide [Pom] 10uM, iberdomide [Iber] 1uM and/or mezigdomide [Mezi] 1uM vs DMSO control over 4h)... Exploring the whole proteome of primary patient samples enhances our understanding of mechanisms of resistance and has highlighted potential novel therapeutic targets in IMiD resistance such as CTAG1B/CTAG1A, for which TCR engineered T cells have been studied in solid tumours."
Clinical • Hematological Malignancies • Multiple Myeloma • Solid Tumor • CDC37 • CHAF1B • CRBN • CTAG1A • CTAG1B • DHFR • IKZF1 • NCAPD2 • SDC1
|
|
Sarah Bird1; Fernando Sialana1; Enze Liu2; Brian Walker2; Shannon Martin1; Marc Leiro1; Ananya Sukhtankar1; Salomon Morales1; Gareth Morgan3; Graham Jackson4; Faith Davies5; Martin Kaiser6; Jyoti Choudhary1; Charlotte Pawlyn6
|